NEW DELHI: The World Health Organization (WHO) has included popular weight-loss drugs like Semaglutide and Tirzepatide, sold in India under the brand name Wegovy and Mounjaro, respectively, in its Model List of Essential Medicines (EML).This is important because the WHO’s model list of essential medicines serves as a basis for public sector procurement, supply of medicines and health insurance, and reimbursement schemes in over 150 countries, including India. If India adopts the list, it could pave the way for a sharp reduction in the prices of these drugs in the future.Currently, Wegovy, one of the most popular weight loss drugs, costs anywhere between Rs 17,000 and Rs 26,000 per month depending on the dosage. Mounjaro, another blockbuster weight-loss drug, costs anywhere between Rs 14,000 and Rs 27,000 per month depending on dosage and the route of administration. Vials are cheaper compared to Kwikpens, a pre-filled, disposable device that contains medication.According to the WHO, the high prices of drugs like Semaglutide and Tirzepatide are limiting access to these medicines. “Prioritising those who would benefit most, encouraging generic competition to drive down prices and making these treatments available in primary care – especially in underserved areas – are key to expanding access and improving health outcomes,” the UN health body has said. Diabetes and obesity are two of the most urgent health challenges facing the world today. In India, studies suggest, the prevalence of overweight and obesity has gone up by over five times in the last 30 years – from approximately 53 million people in 1990 to 235 million in 2021. If action is not taken to curb this growing public health challenge, a recent study published in The Lancet warned, the overweight or obesity prevalence in the country may go up to over 520 million (projected figure) – the second highest globally.As part of broader efforts to reduce inequities in cancer care, the expert committee of WHO has also recommended increasing access to PD-1/PD-L1 immune checkpoint inhibitors.
